The treatment landscape for advanced/metastatic renal cell carcinoma includes well-established angiogenesis and mTOR inhibitors, many of which have broad labels allowing their use across several treatment settings. The approval of the first PD-1 inhibitor in this indication, Opdivo, has begun to have a significant impact on the treatment algorithm, particularly in later-line disease settings.

Table of contents

  • Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (EU5)
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Majority of Newly Diagnosed Renal Cell Carcinoma Patients Managed by Medical Oncologists Present with Advanced or Metastatic Disease
        • Initial Diagnosis by Stage of Disease
        • Sites of First Metastases in Renal Cell Carcinoma
        • Use of Risk Assessment for Stage I-III Renal Cell Carcinoma
        • Risk Classification in Stage I-III Renal Cell Carcinoma
      • Treatment Practices: Newly Diagnosed Patients
        • Sutent Is the Patient Share Leader in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Antineoplastic Drug Therapy Is the Standard Treatment Option for Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment
        • Radical Nephrectomy Is the Most Common Nonpharmacological Treatment for Newly Diagnosed Locally Advanced Renal Cell Carcinoma Patients
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients
        • Sutent Is the Patient-Share Leader in the First-Line Advanced/Metastatic Renal Cell Carcinoma Setting
        • Patient Share in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Average Duration of Treatment for First-Line Sutent and Votrient in Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Is 11 Months
        • Treatment Duration in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Votrient Enjoys the Highest Compliance Rate Among All Therapies for Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Therapy Discontinuation Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma Patients
        • A Significantly Higher Percentage of Locally Advanced vs. Localized Renal Cell Carcinoma Patients Relapse to Metastatic Disease
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma Patients
      • Treatment Practices: Recurrent Patients
        • Drug Treatment Is Typically Administered to Recurrent Renal Cell Carcinoma Patients
        • Drug-Treatment Rates for Recurrent Advanced/Metastatic Renal Cell Carcinoma Decline in Later Lines of Treatment
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment
        • The Majority of Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Do Not Receive Nonpharmacological Treatment
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients
        • Sutent Captures the Highest Patient Share in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Patient Share in Recurrent Advanced/Metastatic Renal Cell Carcinoma
        • Actual Treatment Durations Are Shorter Than Those Intended Across All Lines of Therapy
        • Treatment Duration in Recurrent First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Therapy Compliance Rates Decrease as Patients Progress Through Lines of Treatment
        • Compliance Rate in Recurrent Advanced/Metastatic Renal Cell Carcinoma
        • Mortality During Treatment Increases in Later Lines of Treatment
        • Disease Progression in Recurrent Renal Cell Carcinoma
      • Sequencing of Treatment
        • An Optimal Treatment Sequence in Advanced/Metastatic Renal Cell Carcinoma Is Not Established
        • Sequencing of Treatment for Advanced/Metastatic Renal Cell Carcinoma Patients
      • Recent/Anticipated Changes in Brand Usage/Treatment Approach
        • Prescribing of Votrient and Inlyta Is Increasing for Treatment of Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Statement Agreement
    • Physician Insight on Medical Practice
      • Key Findings
      • Drivers of Treatment Selection
        • Efficacy and Treatment-Related Side Effects Heavily Influence Therapy Selection in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Efficacy Is the Major Driver of Physician Prescribing in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Major Drivers of Brand Usage/Treatment: Sutent
        • Major Drivers of Brand Usage/Treatment: Votrient
        • Major Drivers of Brand Usage/Treatment: Nexavar
        • Major Drivers of Brand Usage/Treatment: Inlyta
        • Major Drivers of Brand Usage/Treatment: Torisel
        • Major Drivers of Brand Usage/Treatment: Afinitor
        • High Incidence of Grade 3/4 Adverse Events Is the Main Obstacle to Prescribing in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Major Obstacles to Brand Usage/Treatment: Sutent
        • Major Obstacles to Brand Usage/Treatment: Votrient
        • Major Obstacles to Brand Usage/Treatment: Nexavar
        • Major Obstacles to Brand Usage/Treatment: Inlyta
        • Major Obstacles to Brand Usage/Treatment: Torisel
        • Major Obstacles to Brand Usage/Treatment: Afinitor
        • Treatment-Related Adverse Effects Is a Major Factor for Treatment Discontinuation in First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Rationale for Therapy Discontinuation: Sutent
        • Rationale for Therapy Discontinuation: Votrient
        • Rationale for Therapy Discontinuation: Nexavar
        • Rationale for Therapy Discontinuation: Inlyta
        • Rationale for Therapy Discontinuation: Torisel
        • Rationale for Therapy Discontinuation: Afinitor
      • Face-to-Face Product Detailing Effectiveness
        • Detailing Visits for Key Advanced/Metastatic Renal Cell Carcinoma Therapies Are frequent and Effective
        • The Majority of Surveyed Oncologists Had Contact with a Sales Representative for Key First-Line Advanced/Metastatic Renal Cell Carcinoma Therapies
        • Face-to-Face Product Detailing
        • Sales Representative Satisfaction Ratings Are High for All Advanced/Metastatic Renal Cell Carcinoma Therapies
        • Satisfaction with Sales Representatives' Knowledge of Therapies for Advanced/Metastatic Renal Cell Carcinoma
        • Satisfaction with Sales Representatives' Ability to Address Questions
        • Satisfaction with Sales Representatives' Overall Effectiveness in Bringing Value to Physician's Practice
        • Most Common Topic Discussed in Recent Sales Representative Visits Was Efficacy
        • Topics Discussed During Most Recent Sales Representative Visit
    • Methodology
      • Primary Market Research Methodology
      • Respondent Demographics: Years in Practice
      • Respondent Demographics: Country of Practice
      • Practice Demographics: Practice Setting
      • Practice Demographics: Number of Renal Cell Carcinoma Patients Under Oncologist Care Per Month
      • Practice Demographics: Number of Advanced/Metastatic Renal Cell Carcinoma Patients Under Oncologist Care Per Month
      • Screener Question: Therapies Prescribed for the Treatment of Renal Cell Carcinoma
    • Appendix
      • Physician Prescribing Practices
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: France
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Germany
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Italy
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Spain
        • Newly Diagnosed Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: United Kingdom
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: France
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: Germany
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: Italy
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: Spain
        • Nonpharmacological Approaches for Newly Diagnosed Renal Cell Carcinoma Patients: United Kingdom
        • Treatment Duration in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Therapy Discontinuation Rate in Newly Diagnosed First-Line Advanced/Metastatic Renal Cell Carcinoma: Country-Specific
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: France
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: Germany
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: Italy
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: Spain
        • Disease Progression in Newly Diagnosed Renal Cell Carcinoma: United Kingdom
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: France
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Germany
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Italy
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: Spain
        • Recurrent Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Treatment: United Kingdom
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: France
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: Germany
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: Italy
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: Spain
        • Nonpharmacological Approaches for Recurrent Renal Cell Carcinoma Patients: United Kingdom
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: France
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: Germany
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: Italy
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: Spain
        • Patient Share for Recurrent Advanced/Metastatic Renal Cell Carcinoma: United Kingdom
        • Treatment Duration in Recurrent First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Treatment Duration in Recurrent Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Recurrent First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Recurrent Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Compliance Rate in Recurrent Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Disease Progression in Recurrent Renal Cell Carcinoma
        • Changes in Treatment Approach: First-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Second-Line Advanced/Metastatic Renal Cell Carcinoma
        • Changes in Treatment Approach: Third-Line Advanced/Metastatic Renal Cell Carcinoma
        • Statement Agreement: France
        • Statement Agreement: Germany
        • Statement Agreement: Italy
        • Statement Agreement: Spain
        • Statement Agreement: United Kingdom
      • Physician Insight on Medical Practice
        • Face-to-Face Product Detailing: France (Sales Representative Frequency and Reach)
        • Face-to-Face Product Detailing: Germany
        • Face-to-Face Product Detailing: Italy
        • Face-to-Face Product Detailing: Spain
        • Face-to-Face Product Detailing: United Kingdom
        • Mean Satisfaction Ratings for Sales Representative Attributes
        • Mean Satisfaction Ratings for Sales Representative Attributes: France
        • Mean Satisfaction Ratings for Sales Representative Attributes: Germany
        • Mean Satisfaction Ratings for Sales Representative Attributes: Italy
        • Mean Satisfaction Ratings for Sales Representative Attributes: Spain
        • Mean Satisfaction Ratings for Sales Representative Attributes: United Kingdom

Author(s): Evrim Gurpinar

Evrim Gurpinar, Ph.D., is a Business Insights Analyst in the oncology team at Decision Resources Group.

Prior to joining DRG, Evrim was a Postdoctoral Fellow at the Cancer Research UK Beatson Institute, where he studied the effects of p53 tumor suppressor mutations on cancer cell metabolism. He received his B.S. in Cell and Molecular Biology from Tulane University as a Fulbright Scholar and his Ph.D. from the University of Alabama at Birmingham School of Medicine. His PhD work entailed a preclinical drug development project to identify novel drug candidates for non-small cell lung cancer.


Related Reports

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | DLSFON0009-2020

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Emerging Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of...

View Details

Renal Cell Carcinoma - Epidemiology - Epidemiology Dashboard

DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence...

View Details